Our earlier work indicated that treatment of BC cells with docetaxel induces the transition of BC cells from a CD44+/CD24−/low phenotype to a CD44+/CD24+/high phenotype that is more resistant to docetaxel [24]. This evidence concerns the gene CD44 and breast cancer.